Exclusion criteria
PFO, bleeding, seizure-related, anxiety, cardiac structural abnormalities, cognitive dysfunction, valvular regurgitation, pseudo-seizure, depression, trauma fracture
BLEEDING, SYSTEMIC DISEASE, GASTROINTESTINAL ULCERS, METABOLIC DISEASES, VALVULAR REGURGITATION, PULMONARY HYPERTENSION, PUNCTURE SITE INFECTION

Participants with history of pseudo-seizure.Participants with serious mental illness, such as anxiety or depression.Participants with cognitive dysfunction (Mini-Mental State Examination score ≤ 23).Participants with vascular puncture site infection or difficult puncture.Participants with PFO associated with other cardiac structural abnormalities, such as moderate or higher valvular regurgitation and pulmonary hypertension.Participants who have contraindications for antiplatelet therapy such as open trauma fracture surgery, gastrointestinal ulcers, active bleeding, and visceral bleeding three months before the screening period.Participants with existing severe systemic diseases, such as digestive, circulatory, respiratory, liver, urinary, musculoskeletal, immune, or genetic metabolic diseases, whom researchers judge might be a potential impact on the results of the trial.Participants who received head surgery or neuromodulation.Participants under consideration for seizure-related surgery or any surgery involving general anesthesia, or who were already under general anesthesia four weeks before the screening period.Participants who receive vaccinations during the screening period or four weeks before.Participants preparing for pregnancy or breastfeeding during the trial period or three months after the study.Patients who are participating in other interventional clinical studies during the trial.Participants who are planning to travel or live abroad during the study period and cannot be followed-up.Participants deemed inappropriate by the researchers for other reasons (need for detailed recording).